More recently, the Food and Drug Administration in the United States and European Medicines Agency have approved vemurafenib plus cobimetinib as a combination therapy for patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma [24, 25]. The gene discussed is BRAF; the disease is metastatic melanoma.